IP Library › Granted Patent US 12,496,283
Granted Patent B2
US 12,496,283 · App. 18/911,045 · Granted Dec 16, 2025

Administration of R-beta-hydroxybutyrate and related compounds in humans

Inventors: Ryan Lowery (Tampa, FL); Jacob Wilson (Tampa, FL); Terry Lacore (Melissa, TX); Gary Millet (Salt Lake City, UT)
Assignee: AXCESS GLOBAL SCIENCES, LLC
A61K31/19A61K9/0053A61K31/522A61P3/04A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,496,283
App. No.
18/911,045
Granted
Dec 16, 2025
Kind
B2
Abstract

Beta-hydroxybutyrate compositions formulated for ingestion by oral delivery as a beverage include a liquid carrier, such as water, milk, drinkable liquid, coconut water, watermelon water, or electrolyte water, and beta-hydroxybutyrate, wherein the beta-hydroxybutyrate can be enriched in R-beta-hydroxybutyrate relative to S-beta-hydroxybutyrate, wherein the beta-hydroxybutyrate comprises R-beta-hydroxybutyric acid, S-beta-hydroxybutyric acid, and optionally one or more salts or esters of R-beta-hydroxybutyrate and one or more salts or esters S-beta-hydroxybutyrate.

Claims (33)

1 . A beta-hydroxybutyrate composition formulated for ingestion by oral delivery as a beverage, or as a dietary supplement for addition to water or beverage, to increase blood ketone level in a subject, comprising:

a liquid carrier comprising at least one of water, milk, drinkable liquid, coconut water, watermelon water, or electrolyte water; and

beta-hydroxybutyrate,

wherein the beta-hydroxybutyrate comprises R-beta-hydroxybutyrate and S-beta-hydroxybutyrate and is enriched in R-beta-hydroxybutyrate relative to S-beta-hydroxybutyrate,

wherein the beta-hydroxybutyrate comprises R-beta-hydroxybutyric acid, S-beta-hydroxybutyric acid, and optionally one or more salts or esters of R-beta-hydroxybutyrate and one or more salts or esters S-beta-hydroxybutyrate.

2 . The beta-hydroxybutyrate composition of claim 1 , wherein the R-beta-hydroxybutyrate is a range of approximately 90% to less than 100% by enantiomeric equivalents and the S-beta-hydroxybutyrate is in a range of greater than 0% to approximately 10% by enantiomeric equivalents.

3 . The beta-hydroxybutyrate composition of claim 1 , wherein the R-beta-hydroxybutyrate is a range of 95% to 99% by enantiomeric equivalents and the S-beta-hydroxybutyrate is in a range of 5% to 1% by enantiomeric equivalents.

4 . The beta-hydroxybutyrate composition of claim 1 , wherein the R-beta-hydroxybutyrate is a range of 52% to 89% by enantiomeric equivalents and the S-beta-hydroxybutyrate is in a range of 11% to 48% by enantiomeric equivalents.

5 . The beta-hydroxybutyrate composition of claim 1 , wherein the R-beta-hydroxybutyrate is a range of 53% to 87% by enantiomeric equivalents and the S-beta-hydroxybutyrate is in a range of 13% to 47% by enantiomeric equivalents.

6 . The beta-hydroxybutyrate composition of claim 1 , wherein the composition further comprises at least one additive selected from the group consisting of 1,3-butanediol, butyrate, butyric acid, tributyrin, acetoacetate esters, beta-hydroxybutyrate esters, fatty acids, esters of fatty acids, berberine, berberine metabolites, amino acids, amino acid metabolites, vitamins, minerals, coconut milk powder, flavorings, caffeine, theacrine, colorings, binders, electrolytes, tetrahydrobiopterin, nucleic acids, alpha-ketoglutaric acid, alpha lipoic acid, nutritional co-factors, beta-methyl-beta-hydroxybutyrate, arginine alpha-ketoglutarate, R-alpha lipoic acid, thiamine, NAD+, NADH, riboflavin, FAD+, FADH, riboflavin-5-phosphate, niacin, nicotinic acid, niacinamide, inositol hexanicotinate, pyridoxine, pyridoxal, pyridoxamine, ascorbic acid, ascorbate salts, citric acid, malic acid, sodium benzoate, pyridoxal-5-phosphate, methylcobalamin, cyanocobalamin, adenosylcobalamin, hydroxycobalamin, pantothenic acid, pantetheine, potassium sorbate, acesulfame K, aspartame, sucralose, stevia, monk fruit extract, allulose, prebiotic fibers, xylo-oligosaccharides (XOS), galacto-oligosaccharides (GOS), mannan-oligosaccharides (MOS), isomalto-oligosaccharides (IMO), lipo-oligosaccharides (LOS), xanthan gum, organic gums, thickeners, and suspension agents.

7 . The beta-hydroxybutyrate composition of claim 1 , wherein the composition further comprises R-1,3-butanediol.

8 . The beta-hydroxybutyrate composition of claim 1 , wherein the composition provides a dose of from about 0.1 g to about 50 g of R-beta-hydroxybutyrate.

9 . The beta-hydroxybutyrate composition of claim 1 , wherein the composition provides a dose of from about 0.1 g to about 15 g of R-beta-hydroxybutyrate.

10 . The beta-hydroxybutyrate composition of claim 1 , wherein the beta-hydroxybutyrate comprises at least one beta-hydroxybutyrate salt selected from the group consisting of sodium beta-hydroxybutyrate, potassium beta-hydroxybutyrate, magnesium beta-hydroxybutyrate, calcium beta-hydroxybutyrate, lithium beta-hydroxybutyrate, and amino acid salt of beta-hydroxybutyrate.

11 . The beta-hydroxybutyrate composition of claim 1 , wherein the beta-hydroxybutyrate comprises beta-hydroxybutyric acid and at least one beta-hydroxybutyrate ester.

12 . The beta-hydroxybutyrate composition of claim 1 , wherein the composition is in a dosage form that provides an amount of beta-hydroxybutyrate to cause weight loss, assist weight maintenance, elevate blood ketone level, maintain blood ketone level, reduce blood glucose level, maintain blood glucose level, improve focus, improve energy, improve cognitive function, improve mental acuity, treat traumatic brain injury, treat diabetes, treat neurological disorders, treat cancer, treat inflammatory conditions, suppress appetite, provide anti-aging effects, provide anti-glycation effects, treat epilepsy, treat depression, improve performance, improve muscle mass, improve motor function, increase strength, increase metabolism, promote fat loss, increase fat oxidation, improve body composition, improve mood, or as a medicament.

13 . The beta-hydroxybutyrate composition of claim 1 , wherein the composition is free of medium chain fatty acids and esters thereof.

14 . A beta-hydroxybutyrate composition formulated for ingestion by oral delivery as a beverage, or as a dietary supplement for addition to water or beverage, to increase blood ketone level in a subject, comprising:

a liquid carrier comprising at least one of water, milk, drinkable liquid, coconut water, watermelon water, or electrolyte water; and

beta-hydroxybutyrate,

wherein the beta-hydroxybutyrate comprises R-beta-hydroxybutyrate and S-beta-hydroxybutyrate,

wherein the R-beta-hydroxybutyrate is a range of approximately 90% to less than 100% by enantiomeric equivalents and the S-beta-hydroxybutyrate is in a range of greater than 0% to approximately 10% by enantiomeric equivalents

wherein the beta-hydroxybutyrate comprises R-beta-hydroxybutyric acid, S-beta-hydroxybutyric acid, and one or more salts or esters of R-beta-hydroxybutyrate and one or more salts or esters S-beta-hydroxybutyrate.

15 . The beta-hydroxybutyrate composition of claim 14 , wherein the composition further comprises R-1,3-butanediol.

16 . The beta-hydroxybutyrate composition of claim 14 , wherein the composition provides a dose of from about 0.2 g to about 30 g of R-beta-hydroxybutyrate.

17 . A beta-hydroxybutyrate composition formulated for ingestion by oral delivery as a beverage, dietary supplement, or food product to increase blood ketone level in a subject, comprising:

a liquid carrier comprising at least one of water, milk, drinkable liquid, coconut water, watermelon water, or electrolyte water; and

beta-hydroxybutyrate,

wherein the beta-hydroxybutyrate contains 52% to 89% by enantiomeric equivalents of R-beta-hydroxybutyrate and from 11% to 48% by enantiomeric equivalents of S-beta-hydroxybutyrate,

wherein the beta-hydroxybutyrate comprises R-beta-hydroxybutyric acid, S-beta-hydroxybutyric acid, and optionally one or more salts or esters of R-beta-hydroxybutyrate and one or more salts or esters S-beta-hydroxybutyrate.

18 . The beta-hydroxybutyrate composition of claim 17 , wherein the R-beta-hydroxybutyrate is a range of 53% to 87% by enantiomeric equivalents and the S-beta-hydroxybutyrate is in a range of 13% to 47% by enantiomeric equivalents.

19 . The beta-hydroxybutyrate composition of claim 17 , wherein the R-beta-hydroxybutyrate is a range of 55% to 85% by enantiomeric equivalents and the S-beta-hydroxybutyrate is in a range of 45% to 15% by enantiomeric equivalents.

20 . The beta-hydroxybutyrate composition of claim 17 , further comprising 1,3-butanediol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2024
From: LOWERY, RYAN; WILSON, JACOB; LACORE, TERRY; MILLET, GARY
To: AXCESS GLOBAL SCIENCES, LLC
Reel/Frame 068860/0407 →
Continuity (15)
Continuation In Part 18591994 · Feb 29, 2024
Continuation 18219556 · Jul 7, 2023
Continuation In Part 18217111 · Jun 30, 2023
Continuation 17367206 · Jul 2, 2021
Continuation In Part 17210646 · Mar 24, 2021
Continuation In Part 17157000 · Jan 25, 2021
Continuation In Part 16996509 · Aug 18, 2020
Continuation In Part 16783886 · Feb 6, 2020
Continuation In Part 16783844 · Feb 6, 2020
Continuation In Part 16720211 · Dec 19, 2019
Continuation 16381202 · Apr 11, 2019
Continuation In Part 15491924 · Apr 19, 2017
Provisional Application 62659564 · Apr 18, 2018
Provisional Application 62324798 · Apr 19, 2016
Related Publication 20250032434A1 · Jan 30, 2025
References Cited (400)
US 2238149A · Aeckerle · 1941 [cited by applicant]
US 2976073A · Russell et al. · 1961 [cited by applicant]
US 4139761A · Obrowski · 1979 [cited by applicant]
US 4224503A · Gijzel et al. · 1980 [cited by applicant]
US 4292499A · Kleinschmidt et al. · 1981 [cited by applicant]
US 4627808A · Hughes · 1986 [cited by applicant]
US 4771074A · Lammerant et al. · 1988 [cited by applicant]
US 4969393A · Mahlich et al. · 1990 [cited by applicant]
US 4997976A · Brunengraber et al. · 1991 [cited by applicant]
US 5093044A · Wretlind et al. · 1992 [cited by applicant]
US 5100677A · Veech · 1992 [cited by applicant]
US 5116868A · Chen et al. · 1992 [cited by applicant]
US 5288512A · Seiden · 1994 [cited by applicant]
US 5292774A · Hiraide et al. · 1994 [cited by applicant]
US 5654266A · Chen et al. · 1997 [cited by applicant]
US 5700670A · Yamagishi et al. · 1997 [cited by applicant]
US 6031000A · Nissen et al. · 2000 [cited by applicant]
US 6207856B1 · Veech · 2001 [cited by applicant]
US 6217915B1 · Luchansky et al. · 2001 [cited by applicant]
US 6232345B1 · Hiraide et al. · 2001 [cited by applicant]
US 6316038B1 · Veech · 2001 [cited by applicant]
US 6323237B1 · Veech · 2001 [cited by applicant]
US 6380244B2 · Martin et al. · 2002 [cited by applicant]
US 6613356B1 · Vlahakos · 2003 [cited by applicant]
US 6706756B1 · Fitzpatrick et al. · 2004 [cited by applicant]
US 6835750B1 · Henderson · 2004 [cited by applicant]
US 7351736B2 · Veech · 2008 [cited by applicant]
US 7807718B2 · Hashim et al. · 2010 [cited by applicant]
US 7891287B2 · Miller · 2011 [cited by applicant]
US 8071641B2 · Weiss et al. · 2011 [cited by applicant]
US 8101653B2 · Veech · 2012 [cited by applicant]
US 8124589B2 · Henderson · 2012 [cited by applicant]
US 8344896B2 · Ozanne · 2013 [cited by applicant]
US 8426468B2 · Henderson · 2013 [cited by applicant]
US 8642654B2 · Clarke et al. · 2014 [cited by applicant]
US 8748400B2 · Henderson · 2014 [cited by applicant]
US 9138420B2 · D'Agostino et al. · 2015 [cited by applicant]
US 9186340B2 · Andrews et al. · 2015 [cited by applicant]
US 9211275B2 · Clarke et al. · 2015 [cited by applicant]
US 9435566B2 · Hill et al. · 2016 [cited by applicant]
US 9675577B2 · D'Agostino et al. · 2017 [cited by applicant]
US 9717767B2 · Carpenter et al. · 2017 [cited by applicant]
US 9795580B2 · Weeber et al. · 2017 [cited by applicant]
US 9808481B2 · Ritter et al. · 2017 [cited by applicant]
US 9925164B1 · Hashim · 2018 [cited by applicant]
US 9957246B2 · Stinchcomb et al. · 2018 [cited by applicant]
US 10022409B2 · Carpenter et al. · 2018 [cited by applicant]
US 10051880B2 · Clarke et al. · 2018 [cited by applicant]
US 10088197B2 · Hamagami et al. · 2018 [cited by applicant]
US 10245242B1 · Millet · 2019 [cited by applicant]
US 10245243B1 · Millet · 2019 [cited by applicant]
US 10278961B2 · Lowery et al. · 2019 [cited by applicant]
US 10292592B2 · Marshall et al. · 2019 [cited by applicant]
US 10292952B2 · Millet · 2019 [cited by applicant]
US 10407331B2 · Kamito et al. · 2019 [cited by applicant]
US 10512615B1 · Millet · 2019 [cited by applicant]
US 10588876B2 · Millet · 2020 [cited by applicant]
US 10588877B2 · Arnold · 2020 [cited by applicant]
US 10596128B2 · Millet · 2020 [cited by applicant]
US 10596129B2 · Millet · 2020 [cited by applicant]
US 10596130B2 · Millet · 2020 [cited by applicant]
US 10596131B2 · Millet · 2020 [cited by applicant]
US 10660958B2 · Clarke · 2020 [cited by applicant]
US 10736861B2 · Millet · 2020 [cited by applicant]
US 10792269B2 · Hashim · 2020 [cited by applicant]
US 10925843B2 · Millet · 2021 [cited by applicant]
US 10973786B2 · Millet · 2021 [cited by applicant]
US 10980764B1 · D'Agostino et al. · 2021 [cited by applicant]
US 10980772B2 · Millet · 2021 [cited by applicant]
US 11020362B2 · Millet · 2021 [cited by applicant]
US 11026929B2 · Lowery et al. · 2021 [cited by applicant]
US 11033553B2 · Millet · 2021 [cited by applicant]
US 11103470B2 · Millet · 2021 [cited by applicant]
US 11129802B2 · Millet · 2021 [cited by applicant]
US 11173138B2 · Lowery et al. · 2021 [cited by applicant]
US 11185518B2 · Millet · 2021 [cited by applicant]
US 11202769B2 · Millet · 2021 [cited by applicant]
US 11241403B2 · Millet · 2022 [cited by applicant]
US 11690817B2 · Millet · 2023 [cited by applicant]
US 11793778B2 · Millet · 2023 [cited by applicant]
US 11806324B2 · Millet · 2023 [cited by applicant]
US 11944598B2 · Millet · 2024 [cited by applicant]
US 11950616B2 · Millet · 2024 [cited by applicant]
US 12186297B2 · Millet · 2025 [cited by applicant]
US 12350243B2 · Millet et al. · 2025 [cited by applicant]
US 20010014696A1 · Veech · 2001 [cited by applicant]
US 20010018866A1 · Fischer · 2001 [cited by applicant]
US 20010041736A1 · Veech · 2001 [cited by applicant]
US 20020013339A1 · Martin et al. · 2002 [cited by applicant]
US 20020124370A1 · Deckert et al. · 2002 [cited by applicant]
US 20030022937A1 · Veech · 2003 [cited by applicant]
US 20040138293A1 · Werner et al. · 2004 [cited by applicant]
US 20040266872A1 · Veech · 2004 [cited by applicant]
US 20050129783A1 · Mccleary et al. · 2005 [cited by applicant]
US 20050169968A1 · Elmaleh et al. · 2005 [cited by applicant]
US 20060165777A1 · Solomon et al. · 2006 [cited by applicant]
US 20060275253A1 · Ushida et al. · 2006 [cited by applicant]
US 20070029913A1 · Chen · 2007 [cited by applicant]
US 20070135376A1 · Henderson · 2007 [cited by applicant]
US 20070179197A1 · Henderson · 2007 [cited by applicant]
US 20080058416A1 · Greenwood et al. · 2008 [cited by applicant]
US 20080287372A1 · Henderson · 2008 [cited by applicant]
US 20090131475A1 · Uesugi et al. · 2009 [cited by applicant]
US 20090253781A1 · Veech · 2009 [cited by applicant]
US 20090306221A1 · Guy et al. · 2009 [cited by applicant]
US 20090325984A1 · Costentin et al. · 2009 [cited by applicant]
US 20100041751A1 · Henderson · 2010 [cited by applicant]
US 20100056631A1 · Hisamura et al. · 2010 [cited by applicant]
US 20100113494A1 · Hu et al. · 2010 [cited by applicant]
US 20100197758A1 · Andrews et al. · 2010 [cited by applicant]
US 20100210726A1 · Kuriyama · 2010 [cited by applicant]
US 20100298294A1 · Clarke et al. · 2010 [cited by applicant]
US 20110237666A1 · Clarke et al. · 2011 [cited by applicant]
US 20110287114A1 · Johnson · 2011 [cited by applicant]
US 20120053240A1 · Rathmacher et al. · 2012 [cited by applicant]
US 20120071548A1 · Veech · 2012 [cited by applicant]
US 20120171165A1 · Buck et al. · 2012 [cited by applicant]
US 20120202891A1 · Stinchcomb et al. · 2012 [cited by applicant]
US 20130079406A1 · Veech · 2013 [cited by applicant]
US 20130337116A1 · Petralia · 2013 [cited by applicant]
US 20140256808A1 · Henderson · 2014 [cited by applicant]
US 20140329893A1 · Veech · 2014 [cited by applicant]
US 20140350105A1 · D'Agostino et al. · 2014 [cited by applicant]
US 20140352728A1 · Svensson · 2014 [cited by applicant]
US 20150018415A1 · Veech · 2015 [cited by applicant]
US 20150063140A1 · Yi et al. · 2015 [cited by applicant]
US 20150065571A1 · Clarke et al. · 2015 [cited by applicant]
US 20150132280A1 · Lopez et al. · 2015 [cited by applicant]
US 20150144074A1 · Fujimoto et al. · 2015 [cited by applicant]
US 20150320809A1 · Carpenter et al. · 2015 [cited by applicant]
US 20150363750A1 · Svensson et al. · 2015 [cited by applicant]
US 20160193173A1 · Clarke et al. · 2016 [cited by applicant]
US 20160256411A1 · Aung-Din · 2016 [cited by applicant]
US 20160263071A1 · Borges et al. · 2016 [cited by applicant]
US 20160272603A1 · Kravchenko et al. · 2016 [cited by applicant]
US 20170020844A1 · Galinski · 2017 [cited by applicant]
US 20170029650A1 · Veling et al. · 2017 [cited by applicant]
US 20170172969A1 · D'Agostino et al. · 2017 [cited by applicant]
US 20170258745A1 · Millet · 2017 [cited by applicant]
US 20170266148A1 · D'Agostino et al. · 2017 [cited by applicant]
US 20170290792A1 · Cavaleri · 2017 [cited by applicant]
US 20170296501A1 · Lowery et al. · 2017 [cited by applicant]
US 20170296520A1 · Lowery et al. · 2017 [cited by applicant]
US 20170298339A1 · Hanson et al. · 2017 [cited by applicant]
US 20170304564A1 · Dehaan et al. · 2017 [cited by applicant]
US 20180020699A1 · Steup · 2018 [cited by applicant]
US 20180021274A1 · Arnold · 2018 [cited by applicant]
US 20180021281A1 · Berger · 2018 [cited by applicant]
US 20180055797A1 · Llosa et al. · 2018 [cited by applicant]
US 20180057846A1 · Llosa et al. · 2018 [cited by applicant]
US 20180195096A1 · Veech et al. · 2018 [cited by applicant]
US 20180214399A1 · Spector et al. · 2018 [cited by applicant]
US 20180238586A1 · Sugatani et al. · 2018 [cited by applicant]
US 20190099394A1 · Ari et al. · 2019 [cited by applicant]
US 20190151267A1 · Millet · 2019 [cited by applicant]
US 20190167613A1 · Millet · 2019 [cited by applicant]
US 20190167614A1 · Millet · 2019 [cited by applicant]
US 20190177673A1 · Llosa et al. · 2019 [cited by applicant]
US 20190183220A1 · Takada · 2019 [cited by applicant]
US 20190183820A1 · Millet · 2019 [cited by applicant]
US 20190183821A1 · Millet · 2019 [cited by applicant]
US 20190191755A1 · Garvey et al. · 2019 [cited by applicant]
US 20190209501A1 · Tinsley, M et al. · 2019 [cited by applicant]
US 20190255028A1 · Lowery et al. · 2019 [cited by applicant]
US 20190262293A1 · Millet · 2019 [cited by applicant]
US 20190313682A1 · Nagel · 2019 [cited by applicant]
US 20190321309A1 · Millet · 2019 [cited by applicant]
US 20200030266A1 · Bradley et al. · 2020 [cited by applicant]
US 20200061004A1 · Millet · 2020 [cited by applicant]
US 20200078973A1 · Valeze et al. · 2020 [cited by applicant]
US 20200129463A1 · Lowery et al. · 2020 [cited by applicant]
US 20200140371A1 · Verdin et al. · 2020 [cited by applicant]
US 20200170982A1 · Millet · 2020 [cited by applicant]
US 20200253909A1 · Millet · 2020 [cited by applicant]
US 20200268701A1 · D'Agostino et al. · 2020 [cited by applicant]
US 20210095867A1 · Gururaja et al. · 2021 [cited by applicant]
US 20210106168A1 · Cingolani et al. · 2021 [cited by applicant]
US 20210205241A1 · Millet · 2021 [cited by applicant]
US 20220133673A1 · Millet · 2022 [cited by applicant]
US 20220202760A1 · Greenwood et al. · 2022 [cited by applicant]
US 20230072854A1 · Purpura et al. · 2023 [cited by applicant]
US 20230115966A1 · Wells et al. · 2023 [cited by applicant]
US 20230201145A1 · Millet · 2023 [cited by applicant]
US 20230346721A1 · Millet · 2023 [cited by applicant]
US 20240024265A1 · Millet · 2024 [cited by applicant]
US 20240197668A1 · Millet · 2024 [cited by applicant]
US 20250025434A1 · Millet · 2025 [cited by applicant]
CA 2990927A1 · 2018 [cited by applicant]
CN 86108978A · 1987 [cited by applicant]
CN 1256629A · 2000 [cited by applicant]
CN 1347319A · 2002 [cited by applicant]
CN 1104978C · 2003 [cited by applicant]
CN 1184978C · 2005 [cited by applicant]
CN 1972698A · 2007 [cited by applicant]
CN 101674730A · 2010 [cited by applicant]
CN 101678043A · 2010 [cited by applicant]
CN 101969769A · 2011 [cited by applicant]
CN 102164884A · 2011 [cited by applicant]
CN 104224823A · 2014 [cited by applicant]
CN 105050594A · 2015 [cited by applicant]
CN 106038532A · 2016 [cited by applicant]
CN 106459646A · 2017 [cited by applicant]
CN 106858066A · 2017 [cited by applicant]
CN 108253621A · 2018 [cited by applicant]
CN 109480284A · 2019 [cited by applicant]
CN 111867576A · 2020 [cited by applicant]
CN 112262936A · 2021 [cited by applicant]
DE 102017210992A1 · 2019 [cited by applicant]
EP 0008700A1 · 1980 [cited by applicant]
EP 1112711A1 · 2001 [cited by applicant]
EP 1178748A1 · 2002 [cited by applicant]
EP 1827412A1 · 2007 [cited by applicant]
EP 1915144A2 · 2008 [cited by applicant]
EP 2283834A2 · 2011 [cited by applicant]
EP 1755743B1 · 2013 [cited by applicant]
EP 2976073A1 · 2016 [cited by applicant]
EP 3094321A1 · 2016 [cited by applicant]
EP 3366173A2 · 2018 [cited by applicant]
EP 3446045A1 · 2019 [cited by applicant]
FR 2997302A1 · 2014 [cited by applicant]
GB 2391493A · 2004 [cited by applicant]
ID 201701176 · 2017 [cited by applicant]
JP 11060434A · 1999 [cited by applicant]
JP 2002521330A · 2002 [cited by applicant]
JP 2004035417A · 2004 [cited by applicant]
JP 2008127369A · 2008 [cited by applicant]
JP 5030553B2 · 2012 [cited by applicant]
JP 2015042644A · 2015 [cited by applicant]
JP 5690261B2 · 2015 [cited by applicant]
JP 2015514104A · 2015 [cited by applicant]
JP 2015102323A · 2015 [cited by applicant]
JP 2016514725A · 2016 [cited by applicant]
JP 2016121128A · 2016 [cited by applicant]
JP 2017046688A · 2017 [cited by applicant]
JP 2018158897A · 2018 [cited by applicant]
JP 2018158898A · 2018 [cited by applicant]
JP 2018158899A · 2018 [cited by applicant]
JP 2019533010A · 2019 [cited by applicant]
JP 2020502652A · 2020 [cited by applicant]
JP 2020527583A · 2020 [cited by applicant]
JP 2021504476A · 2021 [cited by applicant]
JP 2021506294A · 2021 [cited by applicant]
JP 2021127322A · 2021 [cited by applicant]
JP 2021193945A · 2021 [cited by applicant]
RU 2345546C2 · 2009 [cited by applicant]
WO 8703808A1 · 1987 [cited by applicant]
WO 9841200A1 · 1998 [cited by applicant]
WO 0004895A2 · 2000 [cited by applicant]
WO 0015216A1 · 2000 [cited by applicant]
WO 0069315A1 · 2000 [cited by applicant]
WO 0370823A2 · 2003 [cited by applicant]
WO 2005077348A1 · 2005 [cited by applicant]
WO 2005107724A1 · 2005 [cited by applicant]
WO 2006029577A1 · 2006 [cited by applicant]
WO 2006061624A1 · 2006 [cited by applicant]
WO 2007115282A2 · 2007 [cited by applicant]
WO 2007138322A1 · 2007 [cited by applicant]
WO 2008005818A1 · 2008 [cited by applicant]
WO 2008021394A2 · 2008 [cited by applicant]
WO 2008024408A2 · 2008 [cited by applicant]
WO 2009089144A1 · 2009 [cited by applicant]
WO 2010021766A1 · 2010 [cited by applicant]
WO 2010104595A1 · 2010 [cited by applicant]
WO 2011101171A1 · 2011 [cited by applicant]
WO 2012019295A1 · 2012 [cited by applicant]
WO 2012024611A1 · 2012 [cited by applicant]
WO 2013057506A1 · 2013 [cited by applicant]
WO 2013150153A1 · 2013 [cited by applicant]
WO 2014153415A2 · 2014 [cited by applicant]
WO 2014153416A1 · 2014 [cited by applicant]
WO 2015063140A1 · 2015 [cited by applicant]
WO 2015071811A1 · 2015 [cited by applicant]
WO 2015156865A1 · 2015 [cited by applicant]
WO 2016123229A1 · 2016 [cited by applicant]
WO 2016149687A1 · 2016 [cited by applicant]
WO 2017156446A1 · 2017 [cited by applicant]
WO 2017165443A1 · 2017 [cited by applicant]
WO 2017165445A1 · 2017 [cited by applicant]
WO 2017182664A1 · 2017 [cited by applicant]
WO 2017184788A1 · 2017 [cited by applicant]
WO 2017208217A2 · 2017 [cited by applicant]
WO 2018055388A1 · 2018 [cited by applicant]
WO 2018089863A1 · 2018 [cited by applicant]
WO 2018114309A1 · 2018 [cited by applicant]
WO 2018132189A1 · 2018 [cited by applicant]
WO 2018175879A1 · 2018 [cited by applicant]
WO 2018187324A1 · 2018 [cited by applicant]
WO 2018187852A1 · 2018 [cited by applicant]
WO 2019018683A1 · 2019 [cited by applicant]
WO 2019104082A1 · 2019 [cited by applicant]
WO 2019108683A1 · 2019 [cited by applicant]
WO 2019118624A1 · 2019 [cited by applicant]
WO 2019200132A1 · 2019 [cited by applicant]
WO 2019204148A1 · 2019 [cited by applicant]
WO 2019237152A1 · 2019 [cited by applicant]
WO 2019237185A1 · 2019 [cited by applicant]
WO 2020041871A1 · 2020 [cited by applicant]
WO 2020092451A1 · 2020 [cited by applicant]
WO 2020257055A1 · 2020 [cited by applicant]
WO 2021178547A1 · 2021 [cited by applicant]
WO 2022040644A2 · 2022 [cited by applicant]
Kossoff, Eric H. et al. “Optimal Clinical Management of Children Receiving the Ketogenic Diet: Recommendations of the International Ketogenic Diet Study Group.” Epilepsia, Feb. 2009; 50(2):304-17. Epub Sep. 23, 2008. [cited by applicant]
Krotkiewski, “Value of VLCD Supplementation with Medium Chain Triglycerides”, Int J Obes Relat Metab Disord, Sep. 2001, 25 (9), pp. 1393-1400. [cited by applicant]
Lang Chaochun, “Healthy fitness and exercise prescription”, Nov. 30, 2013, p. 201. [cited by applicant]
Lannotti et al., “Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice”, Br J Pharmacol, May 2019, vol. 176, No. 10, pp. 1568-1584. [cited by applicant]
Lile et al. Drug Alcohol Depend. 2012, 122 (1-2), 61-69. [cited by applicant]
Lonza, Duocap Capsules, Feb. 16, 2018, https ://web .archive .org/web/20180216001656/https://www.capsugel.com/consumer-health-nutrition-products/duocap-capsules (Year: 2018). [cited by applicant]
Luis Villasenor, “Supplements and Ketogenic Diets—Facts and Myths”, Retrieved from https://www.ketogains.com/2015/09/supplements-and-ketogenic-diets-facts-and-myths/, Sep. 18, 2015, pp. 15. [cited by applicant]
Lytra. G. et al., “Distribution and Organoleptic Impact of Ethyl 3-Hydroxybutanoate Enantiomers in Wine,” J. Agric. Food Chem, vol. 63, Issue 48, 2015, pp. 10484-10491. [cited by applicant]
Maalouf Met al., “Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation,” Neuroscience, New York, NY, US, vol. 145, Issue 1, Mar. … [cited by applicant]
Maalouf Met al., “The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies,” Brain Research Reviews, Elsevier, NL, vol. 59, No. 2, Mar. 1, 2009, pp. 293-315. [cited by applicant]
Maguire et al., “Gut dysbiosis, leaky gut, and intestinal epithelial proliferation in neurological disorders: towards the development of a new therapeutic using amino acids, prebiotics, probiotics, and postbiotics”, Rev… [cited by applicant]
Malo, M. S. et. al., Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota, 2010, Gut, 59, 1476-1484 (Year: 2010). [cited by applicant]
Mangels D.R. et al, “Catechins as Potential Mediators of Cardiovascular Health”, Translational Sciences, vol. 37, No. 5, May 1, 2017, pp. 757-763. [cited by applicant]
Murray, Andrew J., et al. “Novel ketone diet enhances physical and cognitive performance”, The FASEB Journal, No. Dec. 30, 2016. [cited by applicant]
National Center for Biotechnology Information. PubChem Compound Summary for CID 441, 3-Hydroxybutyric acid, https://pubchem.ncbi.nlm.nih.gov/compound/3-Hydroxybutyric-acid. (Year: 2005). [cited by applicant]
Newman et al. “B-Hydroxybutyrate: A Signaling Metabolite”, Annu Rev Nutr., Aug. 21, 2017, pp. 1-30. [cited by applicant]
Newman et al., “B-hydroxybutyrate: Much more than a metabolite”, Diabetes Res Clin Pract., Nov. 2014. [cited by applicant]
Non-Final Rejection Mailed on Sep. 9, 2020 for U.S. Appl. No. 16/783,956. [cited by applicant]
Nova Max Plus Glucose and Ketone Testing with One Monitor. Downloaded Apr. 1, 2015. http://www.novacares.com/nova-max-plus/. [cited by applicant]
O'Mailey et al, Appl. Physiol. Nutr. Metab. 42: 1031-1035 (2017) Published at www.NRCRESEARCHPRESS.com/APNM on Jul. 27, 2017. [cited by applicant]
O'Meara, Cyndi, Changing Habits, Ketosis—Can we achieve it in a pill?, https://changinghabits. com.au/ketosis-can-we-achieve-it-in-a-pill/, 12 pages, (Jan. 13, 2017). [cited by applicant]
Office Action received for European Patent Application No. 17786592.0, mailed on Jun. 17, 2022, 7 pages. [cited by applicant]
Office Action received for European Patent Application No. 17786592.0, mailed on Sep. 25, 2020, 7 pages. [cited by applicant]
Office Action received for European Patent Application No. 19788264.0, mailed on Mar. 13, 2024, 5 pages. [cited by applicant]
Office Action received for European Patent Application No. 19880284.5, mailed on Nov. 9, 2023, 5 pages. [cited by applicant]
Office Action received for European Patent Application No. 20805593.9, mailed on Dec. 22, 2023, 7 pages. [cited by applicant]
Paraxanthine-Pubchem—2023 (Year: 2023). [cited by applicant]
Parker, Steve, “Ketogenic Mediterraanean Diet: Version 2.3,” Nov. 23, 2010, pp. 1-3. (Year: 2010). [cited by applicant]
Partial supplementary European search report (EPO Form 1507US) issued by the European Patent Office on Sep. 21, 2016 for corresponding European Application No. 14770025.6. [cited by applicant]
Pete J Cox et al., “Acute nutritional ketosis: implications for exercise performance and metabolism,” Extreme Physiology & Medicine, vol. 3, Issue 1, Dec. 1, 2014, pp. 1-9. [cited by applicant]
Precision Xtra vs. NovaMax Plus: Ketone Meter Evaluation. Jimmy Moore's Livin' La Vida Low Garb Blog. Downloaded Apr. 1, 2015. http://livinlavidalowcarb.com/blog/precision-xtra-vs-novamax-plus-ketone-meter-evaluation/15… [cited by applicant]
Pubchem, “Acetoacetic acid” Electronic Resource: https://pubchem.ncbi.nim.nih.gov/compound/Acetoacetic-acid, Retrieved on Sep. 3, 2019. [cited by applicant]
Rho et al. “Acetoacetate, Acetone, and Dibenzylamine (A Contaminant in L-(+)-Beta-Hydroxybutyrate) Exhibit Direct Anticonvulsant Actions in Vivo”, Epilepsia, Raven Press Ltd, New York, US, vol. 43, No. 4, Apr. 1, 2002 (… [cited by applicant]
Rich A.J., “Ketone Bodies as Substrates,” Proceedings of the Nutrition Society (1990), vol. 49, 361-373. [cited by applicant]
Robson et al. Expert Opin. Drug Saf. (2011), vol. 10, pp. 675-685 (Year: 2011). [cited by applicant]
Roeder, Lois M., et al. The Effects of Ketone Bodies, Bicarbonate, and Calcium on Hepatic Mitochondrial Ketogenesis. Archives of Biochemistry and Biophysics, vol. 217, No. 2, Sep. pp. 460-467, 1982. [cited by applicant]
Sajewicz et al. In Journal of Liquid Chromatography & Related Technologies, 33:1047-1057 (2010) (Year: 2010). [cited by applicant]
Sanchez, J. I. et al. Arabinoxylan-oligosaccharides (AXOS) affect the protein/carbohydrate fermentation balance and microbial population dynamics of the Simulator of Human Intestinal Microbial Ecosystem, 2009, Microbial… [cited by applicant]
Sara, How do you know which product is right for you? How to choose exogenous ketones, https://ketosupplements.co.uk/how-to-choose-exogenous-ketones/, 10 pages, (Sep. 25, 2017). [cited by applicant]
Search Report and Written Opinion issued by the Intellectual Property Office of Singapore on Apr. 18, 2016 for corresponding Singapore Application No. 11201506780R. [cited by applicant]
Serum Ketones Test. MedlinePlus Medical Encyclopedia. Downloaded Apr. 1, 2015. http://www.nlm.nih.gov/medlineplus/ency/article/003498.htm. [cited by applicant]
Shigeno et al. in Biosci. Biotech. Biochem., 56(2), 320-323 (1992) (Year: 1992). [cited by applicant]
Short, Jay, Effects of A Ketone/Caffeine Supplement On Cycling and Cognitive Performance, Master's thesis, Ohio State University, 61 pages, (Jan. 1, 2017). [cited by applicant]
Slavin, J. Fiber and Prebiotics: Mechanisms and Health Benefits, 2013, Nutrients, 5: 1417-1425 (Year: 2013). [cited by applicant]
Sorensen et al. (“Simultaneous determination of B-hydroxybutyrate and B-hydroxy-B-methylbutyrate in human whole blood using hydrophilic interaction liquid chromatography electrospray tandem mass spectrometry”, Clinical … [cited by applicant]
Stefan et al., “The Effects of Exogenous Beta-Hydroxybutyrate Supplementation on Metrics of Safety and Health”, International Journal of Nutrition and Food Sciences, vol. 9, No. 6, Nov. 2020, pp. 154-162. [cited by applicant]
Stubbs et al., “On the Metabolism of Exogenous Ketones in Humans”, frontiers in Physiology, vol. 8, 2017, 13 pages. [cited by applicant]
Supplementary European Search Report received for EP Patent Application No. 17786592.0, mailed on Nov. 25, 2019, 10 pages. [cited by applicant]
Tanaka, J., et al., “Significance of Blood Ketone Body Ration as an indicator of Hepatic Cellular Energy Status in Jaundiced Rabbits”, Gastroenterology, 1979, vol. 76, No. 4, pp. 691-696. [cited by applicant]
The Medical Republic, 2018, Sustained Release Sodium Butyrate Supplement Now Available to Support Management of GI Disorders, https://medicalrepublic.com.au/ sustained-release-sodium-butyrate-supplement-now-available-su… [cited by applicant]
Kackley et al., “A Pre-Workout Supplement of Ketone Salts, Caffeine, and Amino Acids Improves High-Intensity Exercise Performance in Keto-Naïve and Keto-Adapted Individuals”, Journal of the American College of Nutrition… [cited by applicant]
A New Toy Measuring Blood Ketones. Diet Doctor, Aug. 21, 2012. Dowloaded Apr. 1, 2015. http://www.dietdoctor.com/a-new-toy-measuring-blood-ketoones. [cited by applicant]
Allendorfer et al., “Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy”, Epilepsy Behav, May 2017, vol. 70, pp. 349-354. [cited by applicant]
Amazon, “Perfect Keto Perform Pre Workout Powder—Bum Fat for Fuel Energy Supplement Drink Mix for Men and Women—Keto Friendly with Ketone Salts, BCAA, Nitric Oxide & MCT”, Sep. 25, 2017 entire document especially p. 1 R… [cited by applicant]
Anonymous: “Strawberry Pineapple Flavour Pre-Exertion Performance Optimizer”, MINTEL, Database accession No. 5661617, 2018, pp. 4. [cited by applicant]
Arendash et al. “Caffeine and Coffee as Therapeutics Against Alzheimer's Disease”, Journal of Alzheimer's Disease 20, 2010, S117-S126. [cited by applicant]
Arnold, Instant Ketosis?, (2013), Aug. 4, 2013 (retrieved on Apr. 21, 2017), p. 1-3. Retrieved from the internet; URL: <http://patrickarnoldblog.com/instant-ketosis/. (Year: 2013). [cited by applicant]
Bala et al. Drug Invention Today. Jun. 1, 2018;10(6), 929-931. [cited by applicant]
Bastin et al., “Salt Slection and Optimisation Procedures for Pharmaceutical New Chemical Entities”, American Chemical Society and The Royal Society of Chemistry, vol. 4, No. 5, 2000, pp. 427-435. [cited by applicant]
Blazquez et al. Journal of Neurochemistry, 1999, vol. 72 No. 4, pp. 1759-1768. (Year: 1999). [cited by applicant]
Budin. N. et al., “Efficient synthesis of the ketone body ester (R)-3-hydroxybutyryl-(R)-3-hydroxybutyrate and its (S,S) enantiomer,” Bioorganic Chemistry, vol. 80, Oct. 2018, pp. 560-564. [cited by applicant]
Clarke, et al., Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. Aug. 2012; 63(3):401-8. [cited by applicant]
Craciun, S. et al. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme, 2012, PNAS, 109 (52): 21307-21312 (Year: 2012). [cited by applicant]
Cresci, G. et al., Lactobacillus GG and Tributyrin Supplementation Reduce Antibiotic-Induced Intestinal Injury, 2013, Journal of Parenteral and Enteral Nutrition, 37(6), 1-20 (Year: 2013). [cited by applicant]
Daniells, Stephen, ‘This is caffeine-evolved’: Ingenious Ingredients co-founder talks up potential of paraxanthine, Nov. 3, 2021, 2 pages, retrieved from https://www.nutraingredients-usa.com/Article/2021/11/03/This-is-c… [cited by applicant]
Database GNPD Mintel, Sep. 29, 2016, anonymous, “Blue Lemon Ice Advanced Formula”, XP093048090, Database accession No. 4315637, pp. 3. [cited by applicant]
Decision to grant received for European Patent Application No. 17786592.0, mailed on Nov. 3, 2023, 2 pages. [cited by applicant]
Dedkova et al. “Role of B-hydroxybutyrate, its polymer poly-b-hydroxybutyrate and inorganic polyphosphate in mammalian health and disease”, Frontiers in Physiology, Jul. 17, 2014, pp. 1-22. [cited by applicant]
Dietary Guidelines Recommendations at https://health.gov/our-work/food-nutrition/2015-2020-dietary-guidelines/guidelines/ appendix-7/ (2010) (retrieved from the internet Oct. 20, 2020) (Year: 2010). [cited by applicant]
Dolson, Laura. How to Test Your Blood for Ketones. Downloaded Apr. 1, 2015. http://lowcarbdiets.about.com/od/KetogenicDiets/a/How-to-Test-Blood-For-Ketones.htm. [cited by applicant]
Energy Times—“Herbal Keto Support”, Jan. 15, 2008 (5 pages). [cited by applicant]
English translation of WO2013057506 accessed form patentscope.wipo.com Jul. 14, 21. [cited by applicant]
Enhancing Human Performance: Ketones. Blue Sky Fact Finding Meeting, Oct. 24, 2012. [cited by applicant]
European Search Report received for EP Patent Application No. 19880284.5, mailed on Jul. 12, 2022, 11 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 20755289.4, mailed on Oct. 11, 2022, 7 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 20755994.9, mailed on Sep. 21, 2022, 6 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 20805593.9, mailed on Dec. 16, 2022, 9 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 21750261.6, mailed on Feb. 2, 2024, 10 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 21862356.9, mailed on Jul. 1, 2024, 10 pages. [cited by applicant]
Extended European Search Report issued in PCT/US2017021886 dated Oct. 17, 2019. [cited by applicant]
Extended European Search Report pursuant to Rule 62 EPC (EPO Form 1507S) issued on Jan. 24, 2017 for corresponding European Patent Application No. 14770025.6. [cited by applicant]
Extended European Search Report received for EP Patent Application No. 19788264.0, mailed on Dec. 20, 2021, 11 pages. [cited by applicant]
Extended European Search Report received for EP Patent Application No. 20755770.3, mailed on Sep. 1, 2022, 7 pages. [cited by applicant]
First Examination Report for New Zealand Patent Application No. 711433 issued by the New Zealand Intellectual Property Office dated Mar. 10, 2016. [cited by applicant]
First Office Action issued by the Chinese State Intellectual Property Office on Nov. 4, 2016 for corresponding Chinese Patent Application No. 201480016818.0. [cited by applicant]
Grootaert, C. Comparison of prebiotic effects of arabinoxylan oligosaccharides and inulin in a simulator of the human intestinal microbial ecosystem, 2009, FEMS Microbiology Ecology, 69: 231-242 (Year: 2009). [cited by applicant]
Haces M L et al: “Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions”, Experimental Neurology, Elsevier, Amsterdam, NL, vol. 211, No. 1, May 1… [cited by applicant]
Hashim, Sami A., et al., “Ketone body therapy: from the ketogenic diet to the oral administration of ketone ester”, Journal of Lipid Research, vol. 55, 2014. [cited by applicant]
Haywood A, Glass BD. Pharmaceutical excipients—where do we begin? Australian Prescriber. 2011; 34: 112-114. [cited by applicant]
Henderson, Samuel T. “Ketone Bodies as a Therapeutic for Alzheimer's Disease.” Neurotherapeutics. Jul. 2008; 5 (3):470-80. [cited by applicant]
Holscher, H. Dietary fiber and prebiotics and the gastrointestinal microbiota, 2017, Gut Microbes, 8(2): 172-184 (Year: 2017). [cited by applicant]
Holtzman et al., “Role of adenosine receptors in caffeine tolerance”, J. Pharmacol. Exp. Ther., 1991 ; 256(1 ): 62-68. [cited by applicant]
Huang Dexiang et al., “Clinical Intravenous Nutrition”, Shanghai Medical University Press Jan. 31, 1994, pp. 121-124. [cited by applicant]
Huang Dexiang, “Clinical Intravenous Nutrition”, Shanghai Medical University Press, Apr. 17, 2023, pp. 1-5. [cited by applicant]
Ichim, T. et al., Experimental support for the effects of a probiotic/digestive enzyme supplement on serum cholesterol concentrations and the intestinal microbiome, 2016, Journal of Translational Medicine, 14(184), 1-9 … [cited by applicant]
Intention to grant received for European Patent Application No. 17786592.0, mailed on Jun. 27, 2023, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US17/28465, mailed on Nov. 1, 2018, 7 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US17/28466, mailed on Nov. 1, 2018, 8 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US19/58676, mailed on May 14, 2021, 6 pages. [cited by applicant]